Načítá se...
CDK4/6 inhibition in cancer: the cell cycle splicing connection
Cyclin-dependent kinase −4 and −6 (CDK4/6) inhibitors are currently being assessed in clinical trials for the treatment of many cancers including melanoma. While investigating the mechanisms of CDK4/6 inhibitor resistance in melanoma, we uncovered a mechanism of action of these inhibitors in regulat...
Uloženo v:
| Vydáno v: | Mol Cell Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6816418/ https://ncbi.nlm.nih.gov/pubmed/31692881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2019.1673643 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|